Central anticholinergic drugs are pharmacological agents that block acetylcholine receptors within the central nervous system. Acetylcholine serves as a major excitatory neurotransmitter in both the brain and peripheral nervous systems. In a healthy basal ganglia, a delicate biochemical balance exists between dopamine, an inhibitory neurotransmitter, and acetylcholine. When dopamine levels drop sharply, such as in Parkinson's disease, acetylcholine becomes relatively overactive, leading to tremors and muscle rigidity. Anticholinergics restore this balance by subduing the excess cholinergic activity.
To exert effects within the central nervous system, these medications must successfully cross the blood-brain barrier. Most central anticholinergics are highly lipid-soluble, allowing them to pass easily through endothelial membranes into cerebral tissues. Once inside, they act primarily as competitive antagonists at muscarinic acetylcholine receptors, specifically the M1 receptor subtype predominantly found in the striatum. By occupying these receptor sites, they prevent endogenous acetylcholine from binding, thereby dampening downstream neuronal signaling pathways responsible for extrapyramidal symptoms.
Central anticholinergics are rarely used as first-line monotherapy for idiopathic Parkinson's disease today, having been largely superseded by levodopa and dopamine agonists. However, they remain highly valuable in specific clinical scenarios:
Because these drugs lack absolute receptor selectivity, blocking acetylcholine triggers widespread adverse reactions affecting both peripheral and central systems. Peripheral effects stem from parasympathetic blockade, manifesting as dry mouth, blurred vision, urinary retention, and constipation. Central anticholinergic syndrome represents severe toxicity, characterized by confusion, hallucinations, agitation, and hyperthermia. Nurses must monitor for signs of acute urinary retention, particularly in elderly male patients with underlying prostatic hyperplasia, and report cognitive changes immediately.
Central anticholinergics are strictly contraindicated in patients with narrow-angle glaucoma, as pupillary dilation can precipitate a dangerous spike in intraocular pressure. They must also be avoided in individuals with gastrointestinal obstruction, paralytic ileus, or severe ulcerative colitis. In older adults, these agents frequently cause cognitive impairment, memory lapses, and delirium due to baseline cholinergic deficits in aging brains. Healthcare providers exercise extreme caution when combining them with other medications possessing anticholinergic properties, such as tricyclic antidepressants or antihistamines, to prevent compounding toxicity.
Comprehensive nursing care involves baseline assessments of mental status, bowel habits, voiding patterns, and visual acuity before initiating therapy. Nurses should educate patients to manage dry mouth using frequent sips of water, sugarless candy, or artificial saliva substitutes. To prevent constipation, encourage adequate fluid intake and high-fiber diets. Instruct patients never to stop these medications abruptly, as doing so can trigger a severe rebound of parkinsonian symptoms or acute cholinergic crisis.